Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Dec. 16, 1998

Clinical studies support excellent safety and efficacy of Busulfex

Dec. 15, 1998

New antitumor compounds presented by Kyorin

Dec. 15, 1998

Oxigene describes mechanism of action, therapeutic potential of declopramide

Dec. 15, 1998

Celgene acquires EntreMed rights to thalidomide

Dec. 14, 1998

AEterna signs CTA with NCI and reports lung cancer pivotal trial protocol details

Dec. 14, 1998

Dendritic cell therapies based on Dendreon technology focus of Dendreon-Kirin partnership

Dec. 14, 1998

Decitabine considered a promising treatment option for high-risk patients with MDS

Dec. 11, 1998

Mouse studies indicate that IL-12 gene therapy is a feasible and effective treatment for AML

Dec. 11, 1998

DDE-261: a novel gigantecin analogue in early development at Wayne Hughes Institute

Dec. 11, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...